University of Toronto Announces Collaboration with Janssen and Johnson & Johnson Innovation

Published on: 

Three-year agreement will support research on treatments for major brain disorders in Neuroscience Catalyst project.

The University of Toronto announced on Sept. 8, 2014 a open innovation collaboration with Janssen facilitated by the J&J Innovation center of California that will support research through the Collaborative Center for Drug Research (CCDR). The three-year agreement will help identify and validate new therapeutic targets that could advance clinical treatment for major brain disorders, including mood disorders and Alzheimer’s disease.

The partnership is intended to enhance discovery and exploration in the field of neuroscience and mental health. Under the terms of the agreement, the CCDR will issue three calls for proposals over three years. Collaborative and open-source research projects will be solicited from researchers at the University of Toronto and its affiliated hospitals through the Toronto Academic Health Science Network. Scientists from Janssen will work with university researchers to provide the drug discovery expertise required to rapidly develop new medicines from basic science innovations.


Source: University of Toronto